ASH 2022 | Investigating the efficacy of CD20 CAR-T cell therapy for WM and CNS lymphoma
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, briefly describes an ongoing multi-center clinical trial investigating the efficacy and safety of CD20 CAR-T cell therapy in patients with Waldenström’s macroglobulinemia (WM) and CNS lymphoma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
MEI Pharma: Consultancy; Fate Therapeutics: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Innate Pharma: Consultancy; Epi Lilly: Consultancy; Adaptimmune: Consultancy; AstraZeneca: Consultancy, Research Funding; Epizyme: Consultancy; Mustang Bio: Consultancy, Research Funding; Beigene: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Regeneron: Consultancy; Merck: Consultancy; Adaptive Biotechnologies: Consultancy; Morphosys/Incyte: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Sound Biologics: Consultancy; Kite Pharma: Consultancy; Abbvie: Consultancy, Research Funding; Atara Biotherapeutic: Consultancy, Research Funding; Celgene, a BMS Company: Research Funding; Gilead: Research Funding; Sunesis: Research Funding; Genmab: Research Funding.
